• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey

    2021-04-17 06:55:16NataliaSousaFreitasQueirozFabioVieiraTeixeiraMarinaPamponetMottaLilianaAndradeChebliAdrianoAkiraFerreiraHinoCamilladeAlmeidaMartinsAbelBotelhoQuaresmaAlexandreAugustodePauladaSilvaAdersonOmarMouraoCintraDamiaoRogerioSaa
    World Journal of Gastroenterology 2021年12期

    Natalia Sousa Freitas Queiroz, Fabio Vieira Teixeira, Marina Pamponet Motta, Liliana Andrade Chebli, Adriano Akira Ferreira Hino, Camilla de Almeida Martins, Abel Botelho Quaresma, Alexandre Augusto de Paula da Silva, Aderson Omar Mourao Cintra Damiao, Rogerio Saad-Hossne, Paulo Gustavo Kotze

    Abstract

    BACKGROUND Coronavirus disease 2019 (COVID-19 ) pandemic is still evolving globally, and Brazil is currently one of the most affected countries. It is still debated whether statement: The study was approved by the GEDIIB ethical review board under the protocol No. 002 /2020 on October 28 th,2020 . Informed consent was waived because the survey recruitment was self-selective. In addition, data were de-identified.Individual participant data were not published, which maintained confidentiality in all steps of study analysis. This study was conducted in compliance with regulations stated in the 1975 Declaration of Helsinki.patients with inflammatory bowel disease (IBD) are at a higher risk for developing COVID-19 or its complications.

    AIM To assess geographical distribution of IBD patients at the highest risk and correlate these data with COVID-19 mortality rates in Brazil.

    METHODS The Brazilian IBD Study Group (Grupo de Estudos da Doen?a Inflamatória Intestinal do Brasil) developed a web-based survey adapted from the British Society of Gastroenterology guidelines. The included categories were demographic data and inquiries related to risk factors for complications from COVID-19 . Patients were categorized as highest, moderate or lowest individual risk. The Spearman correlation test was used to identify any association between highest risk and mortality rates for each state of the country.

    RESULTS A total of 3568 patients (65 .3 % females) were included. Most participants were from the southeastern and southern regions of Brazil, and 84 .1 % were using immunomodulators and/or biologics. Most patients (55 .1 %) were at moderate risk, 23 .4 % were at highest risk and 21 .5 % were at lowest risk of COVID-19 complications. No association between the proportion of IBD patients at highest risk for COVID-19 complications and higher mortality rates was identified in different Brazilian states (r = 0 .146 , P = 0 .467 ).

    CONCLUSION This study indicates a distinct geographical distribution of IBD patients at highest risk for COVID-19 complications in different states of the country, which may reflect contrasting socioeconomic, educational and healthcare aspects. No association between high risk of IBD and COVID-related mortality rates was identified.

    Informed consent statement: As this is a cross-sectional survey analyzing anonymous data, and information used derived from an unidentified database, informed consent from each individual was waived.

    Conflict-of-interest statement:Kotze PG reports grants and personal fees from Takeda, grants and personal fees from Pfizer,personal fees from Janssen,personal fees from Abbvie,personal fees from Novartis,personal fees from Ferring, outside the submitted work.

    Data sharing statement: Study data are de-identified. Data are provided only for the approved study. Data will not be shared with anyone outside of the named members of the investigator team.

    STROBE statement: The authors have read the STROBE Statementchecklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

    Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4 .0 )license, which permits others to distribute, remix, adapt, build upon this work non-commercially,and license their derivative works on different terms, provided the original work is properly cited and

    Key Words: Crohn’s disease; Colitis, Ulcerative; COVID-19 ; Inflammatory bowel disease;Brazil

    INTRODUCTION

    The World Health Organization declared coronavirus disease 2019 (COVID-19 ) a pandemic on March 11 , 2020 . Although many countries are already registering a reduction in the incidence of infections and starting vaccination programs, Brazil is the use is non-commercial. See: htt p://creativecommons.org/License s/by-nc/4 .0 /currently one of the leaders in the world on a daily basis for both numbers of new cases and deaths. As of November 28 , 2020 , we have confirmed 6238250 infected patients and 171998 COVID-related deaths[1].

    Available data suggests that patients with inflammatory bowel disease (IBD) are not at a higher risk for severe acute respiratory syndrome coronavirus-2 infection or the development of COVID-19 complications[2 ]. Moreover, the evolution of COVID-19 does not seem to be worse in patients with IBD, irrespective of their treatment. A recent analysis of 525 IBD patients from the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease revealed that increasing age, comorbidities and corticosteroids are associated with worse outcomes of COVID-19 and that treatment with tumor necrosis factor inhibitors (TNFi) was not associated with severe COVID-19 . The number of reported patients exposed to other medical options was insufficient to drive conclusions regarding risk for severe outcomes in this population[3]. Recently, another report from the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease registry aimed to evaluate the association of IBD medications and their combinations on the risk of adverse COVID-19 outcomes. Based on data from over 1400 IBD patients, it was demonstrated that the combination of thiopurines with TNFi and thiopurine monotherapy are associated with a significantly increased risk of severe COVID-19 as compared with TNFi monotherapy. Anti-interleukins and anti-integrins were not associated with a significantly different risk than TNFi monotherapy[4]. Regardless of the risk of IBD medications, it is noteworthy that maintaining patients in remission with steroid-sparing treatments may be crucial during the pandemic period.

    As the effect of immunosuppressive agents in IBD patients remains unclear during the pandemic, the British Society of Gastroenterology has issued guidance on risk stratification for IBD patients depending on medications in use, age, comorbidities and other risk factors[5]. Patients at highest risk for COVID-related complications are those who have a comorbidity and/or are over 70 -years-old and are on any immunosuppressant therapy for IBD. Those of any age that are receiving ≥ 20 mg of prednisolone, undergoing new induction therapy with biologics and immunomodulators (combination therapy) within 6 wk with moderate to severe active disease with short gut syndrome or patients requiring parenteral nutrition are also considered at highest risk for severe COVID-19 outcomes. Patients receiving biological therapy,thiopurines, calcineurin inhibitors, Janus kinase inhibitors or combination therapy are stratified as moderate risk and the remaining IBD patients as lowest risk. Depending on the risk stratification, recommendations can be suggested. Patients at highest risk are advised to self-isolate, while patients at moderate risk or lowest risk should follow strict social distancing or social distancing as for the general population, respectively.Specific guidance on instructions for self-isolation (shielding education) and social distancing measures to reduce spread of the disease within the population and to protect vulnerable groups has been recently issued[6].

    In order to identify Brazilian IBD patients who could be at high risk for COVID-19 complications, a taskforce group from the Brazilian IBD Study Group (Grupo de Estudos da Doen?a Inflamatória Intestinal do Brasil, GEDIIB) developed an anonymous web-based survey that allows self-identification risk assessment adapted from the British Society of Gastroenterology guidelines. Through a decision tree,patients were self-identified into different groups according to their risk of developing COVID-19 complications and received updated information according to their respective group (Table 1 ).

    Currently, Brazil still has one of the fastest growing severe acute respiratory syndrome coronavirus-2 outbreaks in the world with one of the highest mortality rates, just behind the United States. Given that a higher absolute number of deaths in the context of an epidemic may reflect a strained healthcare system and economy,mapping IBD patients at highest risk for COVID-19 complications could help public authorities to delineate protection strategies to this possibly vulnerable population.Our study aimed to assess geographical distribution of IBD patients at highest risk and correlate these data with COVID-19 mortality rates in different states of Brazil.

    MATERIALS AND METHODS

    Data collection and participants

    The GEDIIB COVID taskforce members in collaboration with experts in the field developed a questionnaire and established a decision tree to evaluate IBD patients pertaining to their risk of serious complications from COVID-19 . The national surveywas available on the website (diicovid.com.br). Data was collected from April 14 , 2020 to June 2 , 2020 . An informative article concerning this survey was posted at the official GEDIIB website, official mailing lists for patients and in national IBD patient association communication medias. All identified erroneous reports were removed for higher accuracy of the data.

    Table 1 Recommendations for inflammatory bowel disease patients according to their risk level

    The questionnaire consisted of fourteen questions (Supplementary Table 1 ). The included categories were demographic data (state and city of residence in Brazil, age,sex, smoking status) and questions related to the risk factors for complications from COVID-19 in IBD populations according to current previously published guidance[5 ,6].The questions included IBD medications in use, self-reported comorbidities(hypertension, diabetes, cardiovascular disease and chronic pulmonary disease) and abdominal surgery for IBD performed in the past 30 d. Through a decision tree,patients were categorized as highest, moderate or lowest individual risk for the potential to develop serious complications from COVID-19 and received updated recommendations according to their risk level. Respondents were distributed according to their respective domiciliary states.

    States of the national federation with a proportion of respondents at the highest risk for COVID-19 infection that were higher than the median rate of the overall country were considered for the analysis. Additionally, states with higher COVID-related cumulative mortality rates than the median of the country (as of June 2 , 2020 , the last available date of the survey) were also grouped. A possible correlation of these findings would suggest if there could be any coincidental relation between highest risk for COVID-19 complications and mortality in the same states.

    Statistical analysis

    Demographic and clinical characteristics of the study population were summarized by descriptive statistics. Categorical variables were expressed as absolute counts and percentages and continuous variables as means and standard deviations. Data was presented initially for the total study population. Thereafter, it was organized according to the five Brazilian regions and respective states to evaluate their geographical distribution. The frequencies of patients using each therapeutic IBD regimen in combination with oral steroids were analyzed as subcategories.

    Categorical variables were compared using a Chi-squared test, and continuous data was analyzed using Student’s t-test. A two-tailed P value of 0 .05 was used for statistical significance. The Spearman correlation test was performed to study a possible correlation between the proportion of highest risk patients and COVID-19 cumulative mortality in states with higher rates compared with the median national cutoffs for each variable. Data was exported and analyzed in SPSS Statistics 23 (IBM Corporation, Armonk, NY, United States).

    Data regarding COVID-19 cumulative death rates from March 3 (first death registered in Brazil) to June 2 were obtained from the Brazilian Ministry of Health COVID-19 website, (https://covid.saude.gov.br/). We computed the COVID-19 mortality per 100000 people using the estimated populational data of 2019 available at the Statistical and Geographical Brazilian Institute for each of the Brazilian states and the federal district (https://datasus.saude.gov.br/populacao-residente/). In order to represent the mortality of COVID-19 , we used classification into deciles. ArcMap 10 .3?was used to generate the map representation.

    Ethical considerations

    The study was approved by the GEDIIB ethical review board under the protocol No.002 /2020 on October 28 , 2020 . Informed consent was waived because the survey recruitment was self-selective. In addition, data were de-identified. Individual participant data were not published, which maintained confidentiality in all steps of study analysis. This study was conducted in compliance with regulations stated in the 1975 Declaration of Helsinki.

    RESULTS

    A total of 3568 IBD patients participated in the national web-based survey and had data included. Six patients were excluded from the analysis due to inconsistent reported data. Overall demographic and baseline characteristics of respondents are illustrated in Table 2 . Most respondents (55 .6 %) were 20 -39 -years-old, and 65 .3 % were females. Current smoking status was reported by 5 .1 % of the participants. The states with the highest response rates to the survey were S?o Paulo (29 .6 %), Rio de Janeiro(9 .4 %) Santa Catarina (7 .7 %), Paraná (7 .7 %), Bahia (6 .0 %) and the Federal District(5 .3 %). Details of the distribution of respondents per state are described in Supplementary Table 2 .

    The proportion of patients presenting with at least one self-reported comorbidity was 21 .6 %, and the most prevalent was hypertension (11 .3 %) followed by chronic pulmonary disease (4 .6 %) and recent (< 30 d) IBD-related abdominal surgery (3 .8 %).Most patients (84 .1 %) were on immune-mediated therapy (biologics 51 .3 % and/or immunomodulators 32 .8 %), 34 .2 % of respondents were using aminosalicylates and 13 .3 % had been recently treated with corticosteroids. Demographic, clinical and treatment characteristics by states is presented in Tables 3 and 4 . The uptake of biological therapy was slightly higher among patients from the southeastern (52 .9 %)and southern (52 .2 %) regions compared with those from the northern region (33 .3 %).Demographic, clinical and treatment characteristics by regions are described in detail in Supplementary Table 3 .

    Overall, the majority (55 .1 %) of patients were at moderate risk, 23 .4 % were at highest risk and 21 .5 % were at lowest risk of developing COVID-19 complications. The proportion of IBD patients at highest, moderate and lowest risk for each state is represented in Figure 1 A-C and for each county/city in Supplementary Figure 1 .Thirteen states had higher proportional rates of patients at highest risk than the national median cutoff of 22 .1 % (Amapá, Rio Grande do Norte, Rio de Janeiro, S?o Paulo, Paraná, Amapá, Federal District, Santa Catarina, Ceará, Goiás, Espírito Santo,Acre and Paraíba). Paraíba was the state with the greatest proportion of IBD patients at highest risk (44 .4 %), followed by Acre (37 .5 %), Espírito Santo (29 .9 %) and Goiás(28 .6 %).

    Geographical distribution of cumulative deaths from COVID-19 in Brazil as of June 2 , 2020 by state (per 100000 people) is represented in Figure 1 D. The national mortality

    rate median cutoff in June 2 was 9 .7 /100000 . The 13 states with mortality rates above the national median were Rio Grande do Norte, Maranh?o, Alagoas, Espírito Santo,S?o Paulo, Acre, Roraima, Amapá, Pernambuco, Rio de Janeiro, Pará, Ceará and Amazonas. The states with higher mortality rates were Amazonas (50 .7 ), Ceará (37 .5 ),Pará (35 .3 ), Rio de Janeiro (32 .9 ) and Amapá (28 ).

    Table 2 Demographic, clinical and treatment characteristics from the whole sample of patients

    When crossing overall proportion of highest risk patients with cumulative mortality rates, the Spearman rank correlation coefficient was not statistically significant (r =0 .146 , P = 0 .467 ). These data are illustrated in Figure 2 .

    DISCUSSION

    This web-based survey analyzed important patient and treatment characteristics that could influence the IBD-related risk of having COVID-19 complications at a national level. Brazil is a continental country with different socioeconomic realities between its five different geographic regions (i.e. Northern, Northeastern, Southern, Southeastern and Midwestern). Most patients who participated in the survey were from the southeastern (n = 1886 ) and southern (n = 738 ) regions, which are more developed areas of the country. This may reflect patients who more often follow official mailing lists from the study group (as the call for participation in the survey) and might be treated in IBD tertiary referral centers. This could also mirror a higher prevalence of IBD in these regions of Brazil as compared to others as stated in a systematic review and some population-based studies[7-10]. Indeed, the findings of our study may not reflect a full national reality, as patients from the northern and northeastern regions may have a different IBD treatment profile. In the same line, it is noteworthy that the northern region had the highest proportion of patients with no current IBD medication(17 .6 %), and the southern and southeastern regions the highest proportion of patients under biological therapy (52 .2 % and 52 .9 %, respectively).

    Our study suggests a different geographical distribution of IBD patients at highest risk for COVID-19 complications in different states of the country, which may reflect different socioeconomic, educational and healthcare issues that could potentially have affected our findings. Despite the fact that the states of Paraíba, Acre, Espírito Santo and Goiás had the greatest proportion of patients at highest risk, this was not reflected in higher COVID-related mortality according to official data from the Ministry of Health. Higher mortality for COVID-19 as of June 2 , 2020 (last available date capturing responses in the survey) was observed in the states of Amazonas, Ceará and Rio de Janeiro.

    Nevertheless, a clear correlation between the risk of COVID-19 complications in IBD patients and mortality was not demonstrated according to the Spearman test. This important finding is in tune with other previously published data from IBD cohorts,which did not identify worse COVID-19 disease courses in IBD patients[3 ,11]. This analysis underscores the important finding that the majority of respondents (55 .1 %)were classified at moderate risk, which means that they were currently having adequate IBD treatment with no increased rates of steroid therapy. Despite being treated with immunosuppressant agents, this population may not be as vulnerable as expected[12]. Although this still needs to be proven, speculation is undertaken if the reduction of the COVID-related “cytokine storm” can be achieved with adequate medical therapy for IBD[13]. More studies in this field are warranted. It is important to state that no longitudinal follow-up of these patients was evaluated in this study. The exact number of infected patients with IBD within our sample was out of the focus of the survey.

    When data is analyzed by regions, the proportion of IBD patients at highest risk was 20 %-25 %, and the majority of patients comprised those using immunomodulators or biologics with no active disease, did not undergo recent IBD-related surgery and were not under steroid therapy. This may reinforce the fact that the survey reached more patients who were likely under regular follow-up with their specialists, a common practice in more developed areas. Another important point is that no significant difference between the regions in the low, moderate or high risk of COVID-related complications was demonstrated (P = 0 .118 ; Supplementary Table 2 ). This may also be demonstrated by the fact that even in the same region, a particular state could have adifferent frequency of high risk in comparison to its neighbors. As an example, the proportion of patients at highest risk was 28 .6 % in the state of Goiás and only 14 .3 % in Tocantins and 16 .7 % in Mato Grosso do Sul, all states from the midwestern region.This can also be justified by different types of IBD care and patient profiles in terms of comorbidities between the states, which demonstrates the complexity of analyzing data in a heterogeneous country such as Brazil.

    Table 3 Demographic, clinical and treatment characteristics by states in Brazil

    1 Monotherapy indicates no concomitant biologics or aminosalicylates/6 -mercaptopurine/methotrexate.2 These subcategories represent the frequency of patients in each therapeutic regimen requiring oral steroids.3 Combo therapy refers to biologics plus aminosalicylates/6 -mercaptopurine/methotrexate.5 -ASA: Aminosalicylates; AZA: Azathioprine; 6 -MP: 6 -Mercaptopurine; MTX: Methotrexate; IBD: Inflammatory bowel disease.

    Regarding COVID-related mortality rates in Brazil, it seems clear that the higher rates found in the states of Amazonas, Ceará, Pará, Rio de Janeiro and Amapá reflect difficulties in healthcare in these specific areas. Most of these states belong to less developed regions of the country (northern and northeastern). These are states with chronic difficulties in the public health system over the last decades, with limited resources, reduced numbers of hospitals and consequently disproportional intensive care unit beds per 100000 inhabitants[14 ]. Recent data revealed that Brazil has 15 .6 intensive care unit beds per 100000 inhabitants. Considering only intensive care unit beds from the public health system, the average drops to 7 .1 per 100000 inhabitants,and there are significant differences between the regions of the country. Among the population exclusively dependent on the public health system, 30 .5 % of the Northeast,22 .6 % of the North and 21 % of the Midwest regions live in places without intensive care unit beds[15].

    Socioeconomical limitations may also be illustrated by the assessment of the Human Development Index (HDI) in these states because it is based on three aspects: Health,as measured by life expectancy at birth; Knowledge, as measured by the adult literacy rate; and A decent standard of living, as measured by gross domestic product per capita. Concerning the five geographic regions of Brazil, the first five states with the highest HDI are from the South, Southeast and Midwest regions and the last five states with the lowest HDI are from the North and Northeast regions[16]. Despite the northern and northeastern regions having a lower prevalence of IBD patients, the significant percentage of patients at highest risk for COVID-19 complications might reflect a similar healthcare system limitation, possibly with few available IBD specialists in therespective regions.

    Table 4 Demographic, clinical and treatment characteristics by states in Brazil (continuation of Table 3 )

    1 Monotherapy indicates no concomitant biologics or aminosalicylates/6 -mercaptopurine/methotrexate.2 These subcategories represent the frequency of patients in each therapeutic regimen requiring oral steroids.3 Combo therapy refers to biologics plus aminosalicylates/6 -mercaptopurine/methotrexate.5 -ASA: Aminosalicylates; AZA: Azathioprine; 6 -MP: 6 -Mercaptopurine; MTX: Methotrexate; IBD: Inflammatory bowel disease.

    It is not being an easy task for Brazilian health authorities to deal with the COVID-19 pandemic. The country is facing important economic and political challenges that likely contribute to the significant increase of the number of cases and deaths throughout the country. The Brazilian government has been a recurrent target for scientific and regular media worldwide[17]. We truly hope this manuscript can raise awareness and call the attention from national health authorities with respect to vulnerability of specific populations during this critical period our country is facing.

    The present study is associated with some limitations, which must be considered for adequate interpretation of the results. First, as previously mentioned, the higher proportion of respondents coming from the southeastern and southern regions may not reflect the reality in other states, mostly from the northern and northeastern regions, which have more rural areas and lower HDI. Another important point is that the survey was simple, objective and analyzed a limited number of variables. As an example, even the simple diagnostic difference between ulcerative colitis and Crohn’s disease was not evaluated. Disease activity at the time of the survey was not captured,which could have influenced the results. Data is also derived from self-reported personal and treatment-related characteristics, which may be biased by individual intellectual issues. Important additional limitations of our study include the absence of follow-up of the patients who replied to the survey. By not having this information,we could not describe in detail if patients who had COVID-19 infection continued their medications, possible differences between ulcerative colitis and Crohn’s disease or common manifestations of severe acute respiratory syndrome coronavirus-2 among included patients due to methodological issues. Despite these limitations, the study’s strength is based in the large number of patients who responded to the survey from all states of Brazil, and this represents one of the largest databases regarding COVID-19 risk for complications in IBD patients globally.

    Figure 1 Inflammatory bowel disease patients at low, moderate and high risk for complications of coronavirus disease 2019 and coronavirus disease-related deaths in Brazil by state (per 100000 people). A: Low risk; B: Moderate risk; C: High risk; D: Coronavirus disease 2019 deaths. COVID: Coronavirus disease; IBD: Inflammatory bowel disease.

    CONCLUSION

    In summary, no correlation between the proportion of IBD patients at highest risk for COVID-19 complications and higher mortality rates was identified among Brazilian states. This can be related to the fact that the majority of the IBD patients are at moderate risk, which could possibly reflect adequate treatment and controlled disease.More epidemiological data comparing IBD and COVID-19 outcomes are suggested in large countries such as Brazil to properly position which IBD patients are more vulnerable in this pandemic period.

    Figure 2 Spearman correlation test between the 27 states and cumulative coronavirus disease 2019 mortality rates. No significant correlation was identified (r = 0 .146 , P = 0 .467 ). COVID-19 : Coronavirus disease 2019 ; IBD: Inflammatory bowel disease.

    ARTICLE HIGHLIGHTS

    色播在线永久视频| av有码第一页| 又紧又爽又黄一区二区| 最近最新免费中文字幕在线| 波多野结衣av一区二区av| 我的亚洲天堂| 搡老妇女老女人老熟妇| 757午夜福利合集在线观看| 国内精品久久久久久久电影| 亚洲中文av在线| 欧美精品啪啪一区二区三区| 香蕉国产在线看| 两个人免费观看高清视频| 婷婷精品国产亚洲av| av片东京热男人的天堂| 久久久水蜜桃国产精品网| 动漫黄色视频在线观看| 亚洲欧洲精品一区二区精品久久久| 制服丝袜大香蕉在线| 亚洲av成人不卡在线观看播放网| 国产精品电影一区二区三区| 亚洲av成人av| 在线观看66精品国产| 日韩大码丰满熟妇| 亚洲精品国产精品久久久不卡| 国产成人系列免费观看| 欧美精品亚洲一区二区| 法律面前人人平等表现在哪些方面| 亚洲九九香蕉| 亚洲成人久久性| 亚洲一区高清亚洲精品| 午夜福利免费观看在线| 嫩草影视91久久| 日韩欧美国产在线观看| 岛国视频午夜一区免费看| 亚洲 欧美 日韩 在线 免费| 国产久久久一区二区三区| 亚洲黑人精品在线| 午夜免费观看网址| 精品久久久久久,| 亚洲精品一卡2卡三卡4卡5卡| 99久久综合精品五月天人人| 欧美激情高清一区二区三区| 亚洲国产精品sss在线观看| 亚洲av中文字字幕乱码综合 | 法律面前人人平等表现在哪些方面| 中亚洲国语对白在线视频| 欧美激情 高清一区二区三区| 久久精品国产综合久久久| 两人在一起打扑克的视频| 少妇裸体淫交视频免费看高清 | 制服诱惑二区| 国产私拍福利视频在线观看| 欧美精品亚洲一区二区| 一本精品99久久精品77| 国产精华一区二区三区| 国产精品久久久久久精品电影 | 国产视频一区二区在线看| 午夜激情福利司机影院| 日本精品一区二区三区蜜桃| 一二三四在线观看免费中文在| e午夜精品久久久久久久| 丝袜美腿诱惑在线| 伊人久久大香线蕉亚洲五| 欧美国产精品va在线观看不卡| 国产精品永久免费网站| 在线看三级毛片| 给我免费播放毛片高清在线观看| 国产高清有码在线观看视频 | 少妇熟女aⅴ在线视频| 夜夜躁狠狠躁天天躁| 最新在线观看一区二区三区| 视频在线观看一区二区三区| 亚洲人成77777在线视频| 美女免费视频网站| 精品国产超薄肉色丝袜足j| 热re99久久国产66热| 国产激情久久老熟女| 久久九九热精品免费| 90打野战视频偷拍视频| 国产精品久久久人人做人人爽| 国产视频一区二区在线看| 日韩大尺度精品在线看网址| 久久这里只有精品19| 欧美zozozo另类| 亚洲国产看品久久| 亚洲午夜理论影院| 高潮久久久久久久久久久不卡| 国产精品美女特级片免费视频播放器 | 一边摸一边做爽爽视频免费| 成年女人毛片免费观看观看9| 久久99热这里只有精品18| 欧美成人午夜精品| 两个人看的免费小视频| 日韩有码中文字幕| 他把我摸到了高潮在线观看| 一区二区三区激情视频| 国产视频内射| 亚洲精品中文字幕一二三四区| 午夜福利18| 久久 成人 亚洲| 97超级碰碰碰精品色视频在线观看| 中文字幕另类日韩欧美亚洲嫩草| 精品国产一区二区三区四区第35| 精品不卡国产一区二区三区| 国产激情偷乱视频一区二区| 日韩欧美国产在线观看| 女人被狂操c到高潮| 久久久久国内视频| 亚洲五月天丁香| 国产精品精品国产色婷婷| 免费在线观看完整版高清| 大型黄色视频在线免费观看| 亚洲精品一卡2卡三卡4卡5卡| 看片在线看免费视频| √禁漫天堂资源中文www| 午夜精品在线福利| 欧美在线一区亚洲| 午夜免费观看网址| 亚洲第一av免费看| 日韩免费av在线播放| 又黄又爽又免费观看的视频| 国产av一区在线观看免费| 日韩有码中文字幕| 亚洲aⅴ乱码一区二区在线播放 | www.自偷自拍.com| 一边摸一边做爽爽视频免费| 亚洲中文日韩欧美视频| 熟女少妇亚洲综合色aaa.| 免费在线观看黄色视频的| 久久久国产精品麻豆| 日韩欧美国产在线观看| 女生性感内裤真人,穿戴方法视频| 在线国产一区二区在线| 一卡2卡三卡四卡精品乱码亚洲| 十八禁人妻一区二区| cao死你这个sao货| 啪啪无遮挡十八禁网站| 精品免费久久久久久久清纯| 欧美激情高清一区二区三区| 黄色视频,在线免费观看| 国产黄a三级三级三级人| 天堂√8在线中文| 男女床上黄色一级片免费看| 99精品欧美一区二区三区四区| 18禁黄网站禁片免费观看直播| 波多野结衣av一区二区av| 丁香欧美五月| 一a级毛片在线观看| 美女午夜性视频免费| 欧美av亚洲av综合av国产av| 美女大奶头视频| 日本 av在线| 免费av毛片视频| 亚洲精品粉嫩美女一区| 少妇粗大呻吟视频| 手机成人av网站| 亚洲av成人一区二区三| 亚洲av片天天在线观看| netflix在线观看网站| 国产激情偷乱视频一区二区| 99久久99久久久精品蜜桃| 窝窝影院91人妻| 精品一区二区三区av网在线观看| 国产精品永久免费网站| 麻豆国产av国片精品| 成人午夜高清在线视频 | 女人被狂操c到高潮| 国产极品粉嫩免费观看在线| 久久性视频一级片| 欧美成人一区二区免费高清观看 | 亚洲第一电影网av| 少妇的丰满在线观看| 精品欧美国产一区二区三| 久久精品91无色码中文字幕| 亚洲精品久久国产高清桃花| 69av精品久久久久久| 亚洲精品美女久久av网站| 亚洲av成人av| 亚洲熟妇中文字幕五十中出| 长腿黑丝高跟| 久久精品影院6| 19禁男女啪啪无遮挡网站| 岛国视频午夜一区免费看| 一二三四社区在线视频社区8| 亚洲av日韩精品久久久久久密| 美女高潮到喷水免费观看| 搡老妇女老女人老熟妇| 亚洲熟妇熟女久久| 午夜a级毛片| 国产亚洲精品第一综合不卡| 久久久久亚洲av毛片大全| 亚洲三区欧美一区| 久久久久久久久中文| 成人18禁在线播放| 亚洲第一欧美日韩一区二区三区| 精品熟女少妇八av免费久了| 最近最新中文字幕大全免费视频| 美女高潮到喷水免费观看| 啦啦啦 在线观看视频| 一区二区日韩欧美中文字幕| 丁香欧美五月| 每晚都被弄得嗷嗷叫到高潮| 女同久久另类99精品国产91| 国产精品1区2区在线观看.| 成人欧美大片| 麻豆一二三区av精品| 精品国产乱子伦一区二区三区| www.熟女人妻精品国产| 久久久久国产一级毛片高清牌| 国产熟女午夜一区二区三区| 一级作爱视频免费观看| 非洲黑人性xxxx精品又粗又长| 在线观看免费午夜福利视频| 国产真实乱freesex| 免费在线观看亚洲国产| 老司机福利观看| 免费看日本二区| 婷婷丁香在线五月| 法律面前人人平等表现在哪些方面| 日本一本二区三区精品| 观看免费一级毛片| 成人欧美大片| 欧美绝顶高潮抽搐喷水| 欧美性长视频在线观看| 在线观看免费视频日本深夜| 老司机靠b影院| 不卡一级毛片| 悠悠久久av| 中文字幕另类日韩欧美亚洲嫩草| 此物有八面人人有两片| 亚洲全国av大片| 波多野结衣高清无吗| 久久久国产欧美日韩av| 久久亚洲精品不卡| 一区二区日韩欧美中文字幕| 免费电影在线观看免费观看| 亚洲精品粉嫩美女一区| 国产精品av久久久久免费| 欧美日韩乱码在线| 久久精品成人免费网站| 母亲3免费完整高清在线观看| 中文字幕人妻熟女乱码| 国产视频内射| 亚洲国产精品久久男人天堂| 国产片内射在线| 两个人看的免费小视频| 窝窝影院91人妻| 热re99久久国产66热| 亚洲专区字幕在线| 天天躁夜夜躁狠狠躁躁| 精华霜和精华液先用哪个| 久久人人精品亚洲av| 亚洲欧美日韩无卡精品| 午夜福利18| 久久天堂一区二区三区四区| 免费在线观看完整版高清| 国产黄a三级三级三级人| 男女之事视频高清在线观看| 亚洲精品久久国产高清桃花| 男人操女人黄网站| 午夜免费激情av| 丝袜人妻中文字幕| 久久精品91无色码中文字幕| av超薄肉色丝袜交足视频| 精品久久久久久久末码| 午夜免费激情av| 亚洲色图 男人天堂 中文字幕| 亚洲一卡2卡3卡4卡5卡精品中文| 18美女黄网站色大片免费观看| 国产精品久久视频播放| 亚洲五月婷婷丁香| 一边摸一边抽搐一进一小说| 两性夫妻黄色片| 国产真实乱freesex| 黄片大片在线免费观看| 亚洲国产精品成人综合色| 免费人成视频x8x8入口观看| 俺也久久电影网| 欧美在线一区亚洲| 少妇裸体淫交视频免费看高清 | 国产成人欧美在线观看| 一个人观看的视频www高清免费观看 | 成人特级黄色片久久久久久久| 中文亚洲av片在线观看爽| 黄色成人免费大全| 婷婷精品国产亚洲av| 国产精品亚洲一级av第二区| 精品一区二区三区视频在线观看免费| 精品国产超薄肉色丝袜足j| 亚洲 欧美 日韩 在线 免费| 亚洲电影在线观看av| 久久人人精品亚洲av| 国产成年人精品一区二区| а√天堂www在线а√下载| 99在线视频只有这里精品首页| 级片在线观看| 精品一区二区三区av网在线观看| 老司机深夜福利视频在线观看| 亚洲av五月六月丁香网| 波多野结衣高清无吗| 欧美激情 高清一区二区三区| 亚洲人成77777在线视频| av超薄肉色丝袜交足视频| 女人被狂操c到高潮| 国产成人av激情在线播放| 欧美不卡视频在线免费观看 | 亚洲一区二区三区不卡视频| 又紧又爽又黄一区二区| 999久久久国产精品视频| 国产91精品成人一区二区三区| 久久亚洲真实| 中亚洲国语对白在线视频| 成年免费大片在线观看| 日韩欧美在线二视频| 精品久久久久久久人妻蜜臀av| 欧美日韩瑟瑟在线播放| 精品不卡国产一区二区三区| 男女午夜视频在线观看| 欧美午夜高清在线| 亚洲一码二码三码区别大吗| 黄片大片在线免费观看| 国产区一区二久久| 高清在线国产一区| 国产精品一区二区免费欧美| 女人爽到高潮嗷嗷叫在线视频| 国产精品1区2区在线观看.| 午夜视频精品福利| 神马国产精品三级电影在线观看 | 亚洲,欧美精品.| 身体一侧抽搐| 免费在线观看影片大全网站| 日韩免费av在线播放| 精品国产一区二区三区四区第35| 免费av毛片视频| 亚洲七黄色美女视频| 中亚洲国语对白在线视频| 在线观看午夜福利视频| 精品熟女少妇八av免费久了| 成熟少妇高潮喷水视频| 看黄色毛片网站| 中文亚洲av片在线观看爽| 欧美日本亚洲视频在线播放| 在线天堂中文资源库| 亚洲无线在线观看| а√天堂www在线а√下载| 妹子高潮喷水视频| 91麻豆av在线| 久久欧美精品欧美久久欧美| 国产三级在线视频| 在线十欧美十亚洲十日本专区| 久久午夜亚洲精品久久| 制服诱惑二区| 亚洲免费av在线视频| 中文字幕久久专区| 黄网站色视频无遮挡免费观看| 他把我摸到了高潮在线观看| 色精品久久人妻99蜜桃| 性欧美人与动物交配| 观看免费一级毛片| 又紧又爽又黄一区二区| 他把我摸到了高潮在线观看| 国产精品九九99| 精品免费久久久久久久清纯| 成年人黄色毛片网站| 黄色a级毛片大全视频| 国产黄片美女视频| 99re在线观看精品视频| 99国产综合亚洲精品| e午夜精品久久久久久久| 亚洲精品av麻豆狂野| 亚洲国产欧美日韩在线播放| 亚洲精品国产精品久久久不卡| 青草久久国产| 精品久久久久久久久久免费视频| 麻豆成人av在线观看| 亚洲欧美日韩无卡精品| 国产精品av久久久久免费| 日本一区二区免费在线视频| 久久国产亚洲av麻豆专区| 久久欧美精品欧美久久欧美| 午夜福利免费观看在线| 欧美色欧美亚洲另类二区| 色播在线永久视频| 亚洲全国av大片| 免费av毛片视频| 男女视频在线观看网站免费 | 禁无遮挡网站| 狂野欧美激情性xxxx| 一本综合久久免费| 欧美在线黄色| 免费高清在线观看日韩| 久久久国产成人免费| 中文字幕最新亚洲高清| 日韩精品中文字幕看吧| 啦啦啦免费观看视频1| 国产精品av久久久久免费| 精品一区二区三区四区五区乱码| 国产精品 欧美亚洲| 一级a爱视频在线免费观看| 美女大奶头视频| 搡老妇女老女人老熟妇| 欧美中文日本在线观看视频| 亚洲午夜理论影院| 18禁观看日本| 1024香蕉在线观看| 在线观看免费日韩欧美大片| 中出人妻视频一区二区| 无限看片的www在线观看| 人人妻人人澡欧美一区二区| 国产伦人伦偷精品视频| 亚洲成a人片在线一区二区| 99国产精品99久久久久| 亚洲国产欧美日韩在线播放| 国产成年人精品一区二区| 欧美日韩福利视频一区二区| 一级毛片女人18水好多| 精品一区二区三区视频在线观看免费| 一进一出好大好爽视频| 亚洲色图 男人天堂 中文字幕| 精品久久久久久久人妻蜜臀av| 2021天堂中文幕一二区在线观 | 级片在线观看| 999久久久精品免费观看国产| 免费av毛片视频| www.www免费av| 免费在线观看日本一区| 91字幕亚洲| 一个人免费在线观看的高清视频| 精品午夜福利视频在线观看一区| 日韩国内少妇激情av| 国产精品久久久人人做人人爽| 中亚洲国语对白在线视频| 欧美一级a爱片免费观看看 | 亚洲专区国产一区二区| 99国产综合亚洲精品| 成人午夜高清在线视频 | 亚洲第一av免费看| 色精品久久人妻99蜜桃| 高潮久久久久久久久久久不卡| 2021天堂中文幕一二区在线观 | 国产精品亚洲美女久久久| 日韩 欧美 亚洲 中文字幕| 国产亚洲av嫩草精品影院| 国产亚洲精品综合一区在线观看 | 午夜福利18| 国产精品 国内视频| 日韩大尺度精品在线看网址| 91成人精品电影| 十八禁人妻一区二区| 黄色a级毛片大全视频| av天堂在线播放| 色播亚洲综合网| 欧美最黄视频在线播放免费| 成人三级黄色视频| 在线观看免费日韩欧美大片| 欧美乱码精品一区二区三区| 黄色女人牲交| 99精品久久久久人妻精品| 757午夜福利合集在线观看| 亚洲av成人av| 黄色丝袜av网址大全| 国产亚洲精品第一综合不卡| 亚洲精品久久国产高清桃花| 窝窝影院91人妻| 国产精品久久久av美女十八| www.www免费av| 91在线观看av| 99精品欧美一区二区三区四区| 国产亚洲欧美98| 亚洲中文字幕日韩| 俄罗斯特黄特色一大片| 黄片播放在线免费| 久久国产乱子伦精品免费另类| 欧美乱妇无乱码| 91在线观看av| 欧美激情 高清一区二区三区| 在线看三级毛片| 夜夜看夜夜爽夜夜摸| 国产黄色小视频在线观看| 高潮久久久久久久久久久不卡| 巨乳人妻的诱惑在线观看| 亚洲人成电影免费在线| 日韩精品中文字幕看吧| 黄色视频不卡| www.熟女人妻精品国产| 国产男靠女视频免费网站| 99riav亚洲国产免费| 国产亚洲精品av在线| 美女高潮喷水抽搐中文字幕| 欧美中文综合在线视频| 午夜免费成人在线视频| 俺也久久电影网| 亚洲va日本ⅴa欧美va伊人久久| 国产精品二区激情视频| 可以免费在线观看a视频的电影网站| 国产午夜福利久久久久久| 欧美激情高清一区二区三区| 我的亚洲天堂| 啦啦啦免费观看视频1| 国产极品粉嫩免费观看在线| 老司机在亚洲福利影院| 一个人免费在线观看的高清视频| 级片在线观看| 搡老岳熟女国产| 一进一出抽搐动态| 欧美成人午夜精品| 精品免费久久久久久久清纯| 丁香六月欧美| 黄色女人牲交| 免费看日本二区| 天天躁夜夜躁狠狠躁躁| 欧美黑人巨大hd| 熟妇人妻久久中文字幕3abv| 99在线人妻在线中文字幕| 亚洲国产中文字幕在线视频| www.自偷自拍.com| 一本久久中文字幕| 免费在线观看视频国产中文字幕亚洲| 啦啦啦 在线观看视频| 亚洲国产中文字幕在线视频| 国产爱豆传媒在线观看 | 亚洲七黄色美女视频| 亚洲国产欧美网| 亚洲久久久国产精品| 美女扒开内裤让男人捅视频| 久久久久亚洲av毛片大全| 91国产中文字幕| 色婷婷久久久亚洲欧美| av有码第一页| 人人澡人人妻人| 久久精品国产亚洲av香蕉五月| 免费在线观看亚洲国产| 12—13女人毛片做爰片一| 91国产中文字幕| 午夜激情av网站| 国产亚洲精品久久久久5区| 欧美最黄视频在线播放免费| 亚洲成人国产一区在线观看| 精品午夜福利视频在线观看一区| 亚洲国产精品sss在线观看| 免费在线观看亚洲国产| 亚洲精品中文字幕在线视频| 国产精品久久视频播放| 亚洲午夜精品一区,二区,三区| 午夜亚洲福利在线播放| 久久国产亚洲av麻豆专区| 黄片小视频在线播放| 熟女少妇亚洲综合色aaa.| 亚洲国产毛片av蜜桃av| aaaaa片日本免费| 久久精品人妻少妇| 真人一进一出gif抽搐免费| 中文亚洲av片在线观看爽| 亚洲精华国产精华精| 757午夜福利合集在线观看| 亚洲av电影在线进入| 99精品在免费线老司机午夜| 99热只有精品国产| 午夜久久久在线观看| 人人妻人人澡欧美一区二区| 精品熟女少妇八av免费久了| 黄网站色视频无遮挡免费观看| 亚洲精品av麻豆狂野| 亚洲成人精品中文字幕电影| 热99re8久久精品国产| 亚洲精品在线美女| 高清毛片免费观看视频网站| 亚洲五月色婷婷综合| 色精品久久人妻99蜜桃| 白带黄色成豆腐渣| 人成视频在线观看免费观看| 日韩国内少妇激情av| 俄罗斯特黄特色一大片| 成人欧美大片| 美女高潮到喷水免费观看| 日韩大尺度精品在线看网址| 亚洲av成人av| 我的亚洲天堂| 国产精品九九99| 一级毛片女人18水好多| 久久精品影院6| 啦啦啦观看免费观看视频高清| 国产精品一区二区三区四区久久 | av电影中文网址| 香蕉丝袜av| 亚洲va日本ⅴa欧美va伊人久久| 国产精品av久久久久免费| 香蕉久久夜色| 亚洲性夜色夜夜综合| 一本综合久久免费| 白带黄色成豆腐渣| 国产成人精品久久二区二区91| 99国产精品一区二区三区| 51午夜福利影视在线观看| 女性被躁到高潮视频| 免费人成视频x8x8入口观看| 曰老女人黄片| 麻豆av在线久日| 麻豆成人av在线观看| 一区二区三区精品91| 精品国产亚洲在线| 午夜精品在线福利| 亚洲电影在线观看av| 久久性视频一级片| 久久婷婷成人综合色麻豆| 欧美日韩福利视频一区二区| 国产成人欧美| 欧美色视频一区免费| 欧美一区二区精品小视频在线| 久99久视频精品免费| 亚洲全国av大片| 久久久精品国产亚洲av高清涩受| 国产三级在线视频| 久久草成人影院|